Plasmodium Falciparum Malaria

Categories: Infectious diseases

Aliases & Classifications for Plasmodium Falciparum Malaria

MalaCards integrated aliases for Plasmodium Falciparum Malaria:

Name: Plasmodium Falciparum Malaria 12 15 17 32
Malaria, Falciparum 43 71
Falciparum Malaria 12 15
Malaria Fever, Subtertian 12
Malignant Tertian Fever 12
Malaria Falciparum 54


External Ids:

Disease Ontology 12 DOID:14067
ICD9CM 34 084.0
MeSH 43 D016778
NCIt 49 C34798
SNOMED-CT 67 62676009
ICD10 32 B50 B50.0 B50.9
UMLS 71 C0024535

Summaries for Plasmodium Falciparum Malaria

Disease Ontology : 12 A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever.

MalaCards based summary : Plasmodium Falciparum Malaria, also known as malaria, falciparum, is related to acute kidney failure and schistosomiasis. An important gene associated with Plasmodium Falciparum Malaria is CR1 (Complement C3b/C4b Receptor 1 (Knops Blood Group)), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Rifampicin and chloroquine have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and endothelial, and related phenotypes are hematopoietic system and cellular

Related Diseases for Plasmodium Falciparum Malaria

Diseases related to Plasmodium Falciparum Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 546)
# Related Disease Score Top Affiliating Genes
1 acute kidney failure 31.8 MB IL18 HP
2 schistosomiasis 31.6 TNF IL10 IFNG
3 exanthem 31.5 TNF IL10 IFNG
4 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 31.3 HP HBB G6PD
5 acute kidney tubular necrosis 31.3 TNF MB IL18
6 tetanus 31.3 TNF MB IL10 IFNG
7 disseminated intravascular coagulation 31.3 TNF SELE MB IL10
8 hepatitis a 31.2 TNF IL10 IFNG
9 aspergillosis 31.2 TNF IL18 IL10 IFNG
10 blackwater fever 31.1 MB HP G6PD
11 anemia, autoimmune hemolytic 31.1 HP G6PD CD55
12 lymphopenia 31.1 IL18 IL10 IFNG CD55
13 urinary schistosomiasis 31.0 IL10 IFNG HP
14 chickenpox 31.0 TNF IL10 IFNG
15 dengue disease 31.0 TNF ICAM1 CCL4
16 glucosephosphate dehydrogenase deficiency 31.0 HP HBB G6PD
17 q fever 31.0 TNF IL10 IFNG
18 adult respiratory distress syndrome 30.9 TNF SELE IL10
19 viral hepatitis 30.9 TNF IL10 IFNG G6PD
20 common cold 30.9 TNF IL10 ICAM1
21 purpura 30.9 TNF IL10 IFNG
22 dermatitis 30.9 TNF IL18 IL10 IFNG
23 brucellosis 30.8 TNF IL18 IL10 IFNG
24 sickle cell anemia 30.8 TNF ICAM1 HBB G6PD
25 salmonellosis 30.8 TNF IL18 IL10 IFNG
26 deficiency anemia 30.8 TNF MB HP HBB G6PD
27 hemoglobinuria 30.8 MB HP G6PD CR1 CD55
28 pancytopenia 30.8 IFNG HP DHFR CD55
29 bronchopneumonia 30.8 TNF IL10 HP
30 vasculitis 30.7 TNF SELE IL10 ICAM1
31 immune deficiency disease 30.7 TNF IL18 IL10 IFNG CCL4
32 neuritis 30.7 TNF IL10 IFNG CCL4
33 iron deficiency anemia 30.7 TNF MB G6PD
34 invasive aspergillosis 30.7 IL10 IFNG HBB
35 lung disease 30.6 TNF IL18 IL10 IFNG ICAM1
36 appendicitis 30.6 TNF IL10 IFNG
37 pulmonary edema 30.6 TNF NOS2 IL10 ICAM1 HP
38 acute cystitis 30.6 TNF IL18 IL10
39 pyelonephritis 30.6 TNF IL10 IFNG
40 scrub typhus 30.6 TNF IL18 IL10 IFNG
41 mycobacterium tuberculosis 1 30.6 TNF IL18 IL10 IFNG CCL4
42 plasmodium vivax malaria 30.6 TNF SELE IL10 IFNG ICAM1 G6PD
43 hemophagocytic lymphohistiocytosis 30.5 TNF IL18 IL10 IFNG
44 thrombocytopenia 30.5 TNF SELE IL18 IL10 IFNG ICAM1
45 hemoglobinopathy 30.5 HP HBB G6PD
46 smallpox 30.5 TNF IL18 IFNG ICAM1
47 thalassemia 30.5 HP HBB G6PD CHIT1
48 human immunodeficiency virus type 1 30.4 TNF IL10 IFNG DHPS CR1 CCL4
49 chikungunya 30.4 TNF MIF IL18
50 acute pancreatitis 30.4 TNF MIF IL18 IL10

Graphical network of the top 20 diseases related to Plasmodium Falciparum Malaria:

Diseases related to Plasmodium Falciparum Malaria

Symptoms & Phenotypes for Plasmodium Falciparum Malaria

MGI Mouse Phenotypes related to Plasmodium Falciparum Malaria:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CD36 CD55 DHFR DHPS FCGR2A G6PD
2 cellular MP:0005384 10.3 CD36 DHFR DHPS G6PD HP ICAM1
3 cardiovascular system MP:0005385 10.26 CD36 DHFR G6PD HP ICAM1 IFNG
4 growth/size/body region MP:0005378 10.25 CD36 CD55 DHFR DHPS G6PD ICAM1
5 homeostasis/metabolism MP:0005376 10.24 CD36 CD55 DHFR DHPS G6PD HP
6 immune system MP:0005387 10.2 CD36 CD55 CHIT1 DHFR DHPS FCGR2A
7 mortality/aging MP:0010768 10.03 CD36 CD55 DHFR DHPS FCGR2A G6PD
8 liver/biliary system MP:0005370 9.86 CD36 DHFR HP IFNG IL10 NOS2
9 muscle MP:0005369 9.65 CD36 CD55 DHFR ICAM1 IFNG IL10
10 neoplasm MP:0002006 9.17 HP ICAM1 IFNG IL10 MIF NOS2

Drugs & Therapeutics for Plasmodium Falciparum Malaria

Drugs for Plasmodium Falciparum Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
Primaquine Approved Phase 4 90-34-6 4908
Nevirapine Approved Phase 4 129618-40-2 4463
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
Quinine Approved Phase 4 130-95-0 8549 3034034
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Lumefantrine Approved Phase 4 82186-77-4 6437380
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
Proguanil Approved Phase 4 500-92-5 4923
Atovaquone Approved Phase 4 95233-18-4 74989
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
leucovorin Approved Phase 4 58-05-9 6006 143
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
21 Cytochrome P-450 Enzyme Inhibitors Phase 4
22 Anti-HIV Agents Phase 4
23 Reverse Transcriptase Inhibitors Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Antitubercular Agents Phase 4
26 Chloroquine diphosphate Phase 4 50-63-5
27 Amebicides Phase 4
28 Antimetabolites Phase 4
29 Antirheumatic Agents Phase 4
30 Analgesics, Non-Narcotic Phase 4
31 Analgesics Phase 4
32 Anti-Inflammatory Agents Phase 4
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4
34 Anti-Retroviral Agents Phase 4
35 Red Cinchona Phase 4
36 Artemether, Lumefantrine Drug Combination Phase 4
37 Atovaquone, proguanil drug combination Phase 4
38 Fanasil, pyrimethamine drug combination Phase 4
39 Vitamin B Complex Phase 4
40 Folate Phase 4
41 Folic Acid Antagonists Phase 4
42 Vitamin B9 Phase 4
43 Artemisinine Phase 4
44 Artemisinins Phase 4
Sulfamethoxazole Approved Phase 3 723-46-6 5329
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
Acetaminophen Approved Phase 3 103-90-2 1983
Azithromycin Approved Phase 2, Phase 3 83905-01-5 447043 55185

Interventional clinical trials:

(show top 50) (show all 449)
# Name Status NCT ID Phase Drugs
1 Assessment of in Vivo and in Vitro Efficacy of Combined Artesunate/Mefloquine Therapy for Treatment of Uncomplicated Plasmodium Falciparum Infection in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
2 Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
3 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
4 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics of Lumefantrine and Population Pharmacokinetics of Lumefantrine Among Ugandan Children Unknown status NCT01944189 Phase 4
5 Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
6 Impact of Insecticide Resistance in Anopheles Arabiensis on the Effectiveness of Malaria Vector Control in Sudan Unknown status NCT01713517 Phase 4
7 Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
8 Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
9 Confirmation of Artemisinin Tolerance in Malaria Parasites Trial in Kilifi Unknown status NCT01190371 Phase 4 Artesunate
10 A Randomized, Double Blind Trial on the Efficacy and Safety of Amodiaquine-Artesunate and Amodiaquine Alone in the Treatment of Children With Uncomplicated Falciparum Malaria Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
11 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
12 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
13 A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya Completed NCT00529867 Phase 4 Artemether/lumefantrine tablets;Artemether/Lumefantrine suspension
14 Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes Completed NCT02325180 Phase 4 Dihydroartemisinin-Piperaquine;Artemether-lumefantrine
15 Study of Therapeutic Efficacy, Safety and Pharmacokinetic Interactions Between Artemether-lumefantrine and Nevirapine-based Antiretrovirals in HIV-infected Patients With Uncomplicated Falciparum-malaria in Muheza, Northeastern Tanzania Completed NCT00885287 Phase 4 Artemether-lumefantrine (AL)
16 Safety, Tolerability, Pharmacokinetics and Efficacy, Phase Iv, Open Label Study of Fixed Arco® and Eurartesim® Therapies in Adults and Children With Uncomplicated P. Falciparum Malaria in Tanzania Completed NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
17 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014 Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
18 Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13 Completed NCT01755559 Phase 4 Artesunate-amodiaquine;Dihydroartemisinin-piperaquine;Artemether-lumefantrine
19 A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal Completed NCT00540410 Phase 4 Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination);Coartem® (arthemether+ lumefantrine)
20 A Randomised Study to Compare a Fixed Dose Combination of Artesunate Plus Amiodaquine (Coarsucam) Versus a Fixed Dose Combination of Artemether Plus Lumefantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During the 2 Years of Follow-up, in Children in Uganda. Completed NCT00699920 Phase 4 Coarsucam;Coartem
21 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Five Years After Wide Scale Use of the Drug in Tanzania. Completed NCT02089841 Phase 4 Artemether-lumefantrine
22 Efficacy of Amodiaquine-artesunate in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children at an IPTi Site in Rural Western Kenya Completed NCT00425763 Phase 4 AQAS
23 Open-label, Multi-center, Non-comparative Efficacy, Safety, and Tolerability Study of Co-artemether in the Treatment of Acute Uncomplicated Malaria in Non-immune Patients Completed NCT00233337 Phase 4 Co-artemether
24 Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan Completed NCT01019408 Phase 4 Chloroquine
25 Efficacy and Safety of Artesunate + Amodiaquine Combined With a Single Low Dose of Primaquine (0.25 mg/kg) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Zanzibar Completed NCT03773536 Phase 4 Artesunate-amodiaquine given with single low dose primaquine
26 A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi Completed NCT00164359 Phase 4 Amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate
27 A Multicentre Randomised Comparative Clinical Trial of the Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine (Coartem®) for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Zanzibar Completed NCT03768908 Phase 4 Artemether-lumefantrine;Artesunate + Amodiaquine
28 Assessing the Effectiveness of Targeted Active Case Detection Among High Risk Populations in Southern Lao PDR Completed NCT03783299 Phase 4 Artemether-lumefantrine;Primaquine Phosphate
29 A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Completed NCT00859807 Phase 4 Flavoquine®, Camoquin® Suspension;Flavoquine®, Camoquin® Suspension
30 Randomised, Comparative Study of the Efficacy and Safety of Arsucam® Administered as a Single Daily Intake Versus Two Daily Intakes in the Treatment of Plasmodium Falciparum Malaria Attack Completed NCT00445796 Phase 4 Artesunate;Amodiaquine
31 Randomized Study of the Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate Plus Amodiaquine Coadministered for the Treatment of Uncomplicated Falciparum Malaria in Zanzibar Completed NCT03764527 Phase 4 Artemether-lumefantrine;Coadministered Artesunate plus Amodiaquine
32 Efficacy and Safety of Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania Completed NCT03431714 Phase 4 Artesunate amodiaquine
33 Artemether-lumefantrine Vs Co-formulated Amodiaquine + Artesunate for the Treatment of Uncomplicated Falciparum Malaria: a Randomized Open-label Trial to Evaluate the Effectiveness of the Burkina Faso New Drug Policy Completed NCT01017770 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine
34 An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older Completed NCT00444106 Phase 4 Artesunate-mefloquine;Atovaquone-proguanil;Artemether-lumefantrine
35 Efficacy of Intermittent Sulfadoxine-Pyrimethamine and Sulfadoxine-Pyrimethamine + Artesunate Treatment in the Prevention of Malaria in Pregnancy in an Area With Chloroquine-Resistant Plasmodium Falciparum Completed NCT00164255 Phase 4 sulfadoxine/pyrimethamine;sulfadoxine/pyrimethamine plus artesunate
36 A Nested Open Labeled Study to Compare the Effectiveness and Safety of a Fixed-dose Combination of Artesunate Plus Amodiaquine (ASAQ Winthrop®) in the Unsupervised Treatment of Uncomplicated Plasmodium Falciparum Malaria Attacks in Two Patient Groups Enrolled at Two Year-intervals in a Pilot District of Côte d'Ivoire Completed NCT01023399 Phase 4 Artesunate + Amodiaquine
37 A Phase IV Study on the Safety and Effectiveness of a Fixed-dose Combination of Artesunate and Mefloquine (Artequin[TM] Paediatric) Administered for 3 Days in Children With Uncomplicated Plasmodium Falciparum Malaria in Africa Completed NCT00978172 Phase 4 artesunate and mefloquine
38 Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau. Completed NCT00426439 Phase 4 Chloroquine;Artemether-lumefantrine (Coartem)
39 Chloroquine and Amodiaquine for Treatment of Symptomatic Children With Plasmodium Malaria in Guinea-Bissau Completed NCT00137514 Phase 4 chloroquine;amodiaquine
40 The in-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Individuals-a 28 Day Efficacy Trial Involving HIV+ and HIV- Adults. Completed NCT00144352 Phase 4 sulfadoxine-pyrimethamine
41 Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial Completed NCT02940756 Phase 4 artesunate-amodiaquine;artemether-lumefantrine;Dihydroartemisinine-piperaquine
42 The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians Completed NCT02434952 Phase 4 Dihydroartemisinin piperaquine (DHA PP);Primaquine
43 A Multicentre, Randomised Trial to Detect in Vivo Resistance of Plasmodium Falciparum to Artesunate in Patients With Uncomplicated Malaria. Completed NCT01350856 Phase 4 Artesunate 2;Artesunate 4
44 Pharmacokinetic Study of Multi-dose Chloroquine Completed NCT01814423 Phase 4 Chloroquine-base 50 mg;Chloroquine-base 70 mg
45 Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria Completed NCT00167739 Phase 4 Quinine plus sulfadoxine-pyrimethamine
46 A Non-Inferiority, Open-Labelled, Randomised Trial Of The Efficacy And Safety Of Artesunate-Amodiaquine, Artemether-Lumefantrine, And Artesunate-Lapdap For Treatment Of Uncomplicated P. Falciparum Malaria Among Children In Ghana Completed NCT00119145 Phase 4 artesunate-amodiaquine;coartem;artesunate-lapdap
47 Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax® Completed NCT03201770 Phase 4 pyronaridine artesunate
48 An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi Completed NCT00164710 Phase 4 sulfadoxine-pyrimethamine;amodiaquine plus sulfadoxine-pyrimethamine;amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate;lumefantrine-artemether
49 The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children With Recrudescent Malaria in Guinea-Bissau Completed NCT00137553 Phase 4 Sulfadoxine-pyrimethamine (Fansidar)
50 A Randomised, Open-label Non-inferiority Trial of Artemether-lumefantrine Versus Quinine for the Treatment of Uncomplicated Falciparum Malaria During Pregnancy, Mbarara, Uganda (2006-2007) Completed NCT00495508 Phase 4 Quinine;artemether / lumefantrine

Search NIH Clinical Center for Plasmodium Falciparum Malaria

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Chloroquine hydrochloride
chloroquine phosphate
Halofantrine hydrochloride
Mefloquine Hydrochloride
Primaquine Phosphate
Quinacrine Monohydrochloride
Quinine Sulfate

Cochrane evidence based reviews: malaria, falciparum

Genetic Tests for Plasmodium Falciparum Malaria

Anatomical Context for Plasmodium Falciparum Malaria

MalaCards organs/tissues related to Plasmodium Falciparum Malaria:

Testes, T Cells, Endothelial, Liver, B Cells, Monocytes, Kidney

Publications for Plasmodium Falciparum Malaria

Articles related to Plasmodium Falciparum Malaria:

(show top 50) (show all 4140)
# Title Authors PMID Year
Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. 61 54
19690618 2009
Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea. 61 54
19380468 2009
Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: application to the study of Plasmodium falciparum malaria. 54 61
18671254 2009
FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan. 61 54
19284648 2009
Cortisol, prolactin, cytokines and the susceptibility of pregnant Sudanese women to Plasmodium falciparum malaria. 61 54
19208295 2009
Variations in host genes encoding adhesion molecules and susceptibility to falciparum malaria in India. 54 61
19055786 2008
A functional single-nucleotide polymorphism in the CR1 promoter region contributes to protection against cerebral malaria. 61 54
18954261 2008
Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. 54 61
18972133 2008
dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. 54 61
19055622 2008
A decrease of plasma macrophage migration inhibitory factor concentration is associated with lower numbers of circulating lymphocytes in experimental Plasmodium falciparum malaria. 61 54
18179626 2008
Polymorphisms of TNF-enhancer and gene for FcgammaRIIa correlate with the severity of falciparum malaria in the ethnically diverse Indian population. 54 61
18194515 2008
Complement activation in Ghanaian children with severe Plasmodium falciparum malaria. 54 61
18086298 2007
Fc gamma receptor IIa (CD32) polymorphism and antibody responses to asexual blood-stage antigens of Plasmodium falciparum malaria in Sudanese patients. 61 54
17587350 2007
gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to Plasmodium falciparum malaria. 61 54
17557374 2007
Malarial pigment haemozoin, IFN-gamma, TNF-alpha, IL-1beta and LPS do not stimulate expression of inducible nitric oxide synthase and production of nitric oxide in immuno-purified human monocytes. 54 61
17543124 2007
[Erythrocyte polymorphism in Mali: epidemiology and resistance mechanisms against severe Plasmodium falciparum malaria]. 61 54
18225432 2007
Decreased circulating macrophage migration inhibitory factor (MIF) protein and blood mononuclear cell MIF transcripts in children with Plasmodium falciparum malaria. 54 61
16461006 2006
Complement receptor 1 polymorphisms associated with resistance to severe malaria in Kenya. 61 54
16277654 2005
Carrageenans inhibit the in vitro growth of Plasmodium falciparum and cytoadhesion to CD36. 61 54
16012863 2005
Plasmodium falciparum malaria in south-west Nigerian children: is the polymorphism of ICAM-1 and E-selectin genes contributing to the clinical severity of malaria? 54 61
16002039 2005
High levels of circulating cardiac proteins indicate cardiac impairment in African children with severe Plasmodium falciparum malaria. 54 61
16002312 2005
Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. 54 61
15972509 2005
Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. 61 54
15973412 2005
IFN-gamma and IL-10 mediate parasite-specific immune responses of cord blood cells induced by pregnancy-associated Plasmodium falciparum malaria. 61 54
15661939 2005
Polymorphisms of the HLA-B and HLA-DRB1 genes in Thai malaria patients. 54 61
15728986 2005
Circulating levels of the interleukin (IL)-4 receptor and of IL-18 in patients with Plasmodium falciparum malaria. 54 61
15652447 2005
Interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide promote chitotriosidase gene expression in human macrophages. 61 54
15900564 2005
Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. 54 61
15280204 2004
Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. 54 61
15385460 2004
Circulating concentrations of cardiac proteins in complicated and uncomplicated Plasmodium falciparum malaria. 61 54
15482402 2004
Prolactin induces chitotriosidase gene expression in human monocyte-derived macrophages. 54 61
15234536 2004
Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. 54 61
15279621 2004
Reduced peripheral PGE2 biosynthesis in Plasmodium falciparum malaria occurs through hemozoin-induced suppression of blood mononuclear cell cyclooxygenase-2 gene expression via an interleukin-10-independent mechanism. 54 61
15502882 2004
A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions. 54 61
14647197 2003
CR1 Knops blood group alleles are not associated with severe malaria in the Gambia. 54 61
12847553 2003
Involvement of interleukin-18 in severe Plasmodium falciparum malaria. 54 61
14584384 2003
Human genetic polymorphisms and asymptomatic Plasmodium falciparum malaria in Gabonese schoolchildren. 61 54
12641410 2003
Modulation of immune response in Plasmodium falciparum malaria: role of IL-12, IL-18 and TGF-beta. 54 61
12788305 2003
Plasma levels of interleukin-12 (IL-12), interleukin-18 (IL-18) and transforming growth factor beta (TGF-beta) in Plasmodium falciparum malaria. 61 54
12517727 2002
Plasma levels of interleukin-18 and interleukin-12 in Plasmodium falciparum malaria. 54 61
12654091 2002
Innate immune response to malaria: rapid induction of IFN-gamma from human NK cells by live Plasmodium falciparum-infected erythrocytes. 61 54
12218109 2002
Significant association of longer forms of CCTTT Microsatellite repeat in the inducible nitric oxide synthase promoter with severe malaria in Thailand. 61 54
12195390 2002
Role of Th1 and Th2 cytokines in immune response to uncomplicated Plasmodium falciparum malaria. 61 54
11874876 2002
Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated Plasmodium falciparum malaria. 61 54
11687458 2001
Plasmodium falciparum liver-stage antigen-1 peptide-specific interferon-gamma responses are not suppressed during uncomplicated malaria in African children. 54 61
11781192 2001
Serum levels of interleukin-18 in patients with uncomplicated Plasmodium falciparum malaria. 61 54
11399527 2001
Low interleukin-12 activity in severe Plasmodium falciparum malaria. 61 54
10858202 2000
Haptoglobin 1-1 is associated with susceptibility to severe Plasmodium falciparum malaria. 61 54
10897372 2000
High levels of inducible nitric oxide synthase mRNA are associated with increased monocyte counts in blood and have a beneficial role in Plasmodium falciparum malaria. 61 54
10603415 2000
Circulating receptors implicated in the cyto-adherence occurring in severe Plasmodium falciparum malaria in Thailand. 54 61
10690240 1999

Variations for Plasmodium Falciparum Malaria

Expression for Plasmodium Falciparum Malaria

Search GEO for disease gene expression data for Plasmodium Falciparum Malaria.

Pathways for Plasmodium Falciparum Malaria

Pathways related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
12.81 TNF IL10 IFNG ICAM1 CD55
Show member pathways
12.56 TNF NOS2 IL18 IL10 IFNG
Show member pathways
12.29 TNF IL18 IL10 CCL4
Show member pathways
Show member pathways
Show member pathways
10 12.06 TNF NOS2 IL18 IL10 IFNG FCGR2A
Show member pathways
11.96 NOS2 IL18 IFNG CCL4
12 11.96 TNF IL10 IFNG FCGR2A CD36
Show member pathways
11.92 TNF IL18 IL10 IFNG
15 11.89 TNF NOS2 IL10 IFNG
16 11.86 TNF CR1 CD55 CD36
17 11.86 TNF NOS2 IL18 IL10 ICAM1 CD36
18 11.83 TNF IL18 IFNG ICAM1
19 11.76 SELE IFNG ICAM1
20 11.74 TNF IL18 IL10 IFNG
21 11.72 TNF NOS2 IL10
22 11.7 TNF IL10 IFNG
23 11.58 TNF IL18 CR1
24 11.56 SELE NOS2 IFNG
25 11.49 TNF ICAM1 HP
26 11.49 TNF NOS2 IL18 IFNG
27 11.49 TNF IL18 IL10 ICAM1 CCL4
Show member pathways
29 11.37 NOS2 IFNG ICAM1
Show member pathways
11.33 TNF IL10 IFNG CCL4
31 11.29 TNF IL18 IFNG
32 11.24 TNF IL10 IFNG
33 11.15 IL18 IFNG ICAM1
34 11.07 TNF SELE IL18 IL10 IFNG ICAM1
35 10.98 TNF SELE IL18 IL10 IFNG ICAM1
36 10.9 TNF ICAM1 CD36
37 10.55 NOS2 MB

GO Terms for Plasmodium Falciparum Malaria

Cellular components related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 TNF MIF IL18 IL10 IFNG HP
2 cell surface GO:0009986 9.73 TNF MIF ICAM1 CR1 CD55 CD36
3 tertiary granule lumen GO:1904724 9.5 HP HBB CHIT1
4 extracellular space GO:0005615 9.4 TNF SELE MIF IL18 IL10 IFNG
5 haptoglobin-hemoglobin complex GO:0031838 9.37 HP HBB
6 membrane raft GO:0045121 9.35 TNF SELE ICAM1 CD55 CD36

Biological processes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.97 TNF NOS2 IL10 HP
2 leukocyte migration GO:0050900 9.93 TNF SELE MIF ICAM1
3 negative regulation of gene expression GO:0010629 9.93 TNF NOS2 MIF IFNG CD36
4 response to lipopolysaccharide GO:0032496 9.88 SELE NOS2 IL10 ICAM1
5 inflammatory response GO:0006954 9.88 TNF SELE NOS2 MIF IL18 CCL4
6 immune response GO:0006955 9.87 TNF IL18 IL10 IFNG CHIT1 CD36
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 TNF IL18 ICAM1 CD36
8 viral entry into host cell GO:0046718 9.85 ICAM1 CR1 CD55
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 TNF IL18 IFNG
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 TNF MIF ICAM1 CD36 CCL4
11 regulation of insulin secretion GO:0050796 9.82 TNF NOS2 IFNG
12 response to hydrogen peroxide GO:0042542 9.79 MB HP HBB
13 positive regulation of cell death GO:0010942 9.77 HP HBB CD36
14 cellular response to lipopolysaccharide GO:0071222 9.77 TNF NOS2 IL10 ICAM1 CD36
15 interleukin-12-mediated signaling pathway GO:0035722 9.72 MIF IL10 IFNG
16 cytokine-mediated signaling pathway GO:0019221 9.7 TNF NOS2 IL18 IL10 ICAM1 CD36
17 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IFNG
18 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.67 TNF MIF
19 positive regulation of neuroinflammatory response GO:0150078 9.66 TNF IL18
20 negative regulation of amyloid-beta clearance GO:1900222 9.66 TNF IFNG
21 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL10 IFNG
22 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.64 TNF IFNG
23 endothelial cell apoptotic process GO:0072577 9.64 TNF IL10
24 regulation of removal of superoxide radicals GO:2000121 9.63 DHFR CD36
25 regulation of complement-dependent cytotoxicity GO:1903659 9.62 IL10 CD55
26 positive regulation of killing of cells of other organism GO:0051712 9.61 NOS2 IFNG
27 type 2 immune response GO:0042092 9.61 IL18 IL10
28 negative regulation of cytokine production involved in immune response GO:0002719 9.6 TNF IL10
29 regulation of lipopolysaccharide-mediated signaling pathway GO:0031664 9.58 CD55 CD36
30 negative regulation of cytokine secretion involved in immune response GO:0002740 9.57 TNF IL10
31 positive regulation of cytokine secretion GO:0050715 9.56 TNF MIF IL10 IFNG
32 neutrophil degranulation GO:0043312 9.56 MIF HP HBB FCGR2A CR1 CHIT1
33 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 TNF IFNG
34 receptor biosynthetic process GO:0032800 9.51 TNF IL10
35 positive regulation of blood microparticle formation GO:2000334 9.49 TNF CD36
36 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 TNF IFNG
37 positive regulation of nitrogen compound metabolic process GO:0051173 9.46 TNF IFNG
38 positive regulation of nitric oxide biosynthetic process GO:0045429 9.02 TNF IFNG ICAM1 HBB CD36

Molecular functions related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.43 ICAM1 CR1 CD55
2 hemoglobin binding GO:0030492 9.16 HP HBB
3 NADP binding GO:0050661 9.13 NOS2 G6PD DHFR
4 cytokine activity GO:0005125 9.1 TNF MIF IL18 IL10 IFNG CCL4

Sources for Plasmodium Falciparum Malaria

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....